Drug intelligence / Profile preview

becampanel

Development stage: Preclinical
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

Becampanel is a synthetic small molecule drug of the quinoxalinedione class that acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM). It was developed by Novartis for potential use as an anticonvulsant in epilepsy and was also investigated for neuropathic pain and cerebral ischemia. Becampanel demonstrated significant oral bioavailability (approximately 50% in humans) and has no genotoxic potential in vivo. Despite promising preclinical properties, clinical development was discontinued before completion of trials[1][2][4][5][7].

Other names: becampanelAMP397AMP-397AMP 397

Targets

AMPAR (AMPA receptor)

Beyond the preview

Go deeper on becampanel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on becampanel.

Explore the full profile